Aztreonam(SQ 26776,简称AZT)系新的单环β-内酰胺类中第一个进入临床试验的药物。其结构与传统双环β-内酰胺类(青霉素类和头孢菌素类)不同处在于它只有一个环状结构(单环内酰胺酸),可以全合成制备,化学结构式如下: 胡丕华曾根据1985年美国哥伦比亚“AZT专题讨论会”资料详细综述了AZT的构效关系与抗菌活性等,本文着重于近几年AZT的药理研究及其在临床的试验情况,特别是在儿科感染中的疗效加以综述。 Aztreonam (SQ 26776, referred to as AZT) is the first of the new monocyclic beta-lactams to enter clinical trials. Its structure and the traditional bicyclic β-lactams (penicillins and cephalosporins) is that it has only one ring structure (monocyclic lactamic acid), can be fully synthesized, the chemical structure is as follows: Hu Pihua had according to 1985 The data of AZT Symposium in Columbia, USA provide a detailed overview of the structure-activity relationship and antibacterial activity of AZT. This article focuses on the pharmacological studies of AZT in recent years and its clinical trials, especially in pediatric infections .